MZL

AcronymDefinition
MZLMarginal Zone Lymphoma
MZLMuzzle
MZLManizales, Colombia - Santaguida (Airport Code)
MZLMantle Zone Lymphoma (medical illness)
MZLMinimum Zone Line (see LSZ)
MZLMeyer Zall Laboratories, Pty. Ltd. (est. 1992; South Africa)
References in periodicals archive ?
Epidermotropic MZL represents a distinctive nosologic B-cell lymphoma that should be considered a diagnostic possibility in older men who present with an unexplained papulosquamous eruption resembling pityriasis rosea," the researchers wrote.
1) as assessed by an Independent Review Committee using criteria adopted from the International Working Group criteria for malignant lymphoma, with efficacy observed across all three MZL sub-types.
In conjunction, the primary objective of the company's trial of ORR was achieved in nearly half (46%) of the patients as assessed by an Independent Review Committee (IRC) using criteria adopted from the International Working Group criteria for malignant lymphoma, with efficacy observed across all three MZL sub-types.
11) The MYD88 L265P mutation is not exclusive to LPL because it has also been identified in diffuse large B-cell lymphoma (DLBCL), especially the activated B-cell-like type, (11) primary central nervous system lymphoma, (12) and less frequently in low-grade B-cell lymphomas, such as CLL (13, 14) and MZL.
pylori infection in Pakistan (58%) and despite this high prevalence the number of cases of gastric MZL were not found to be very high in Pakistan151617.
The most likely diagnosis is MZL, but PTLD has not been completely ruled out.
It was fear of Muslim domination that pulled together the various ethnic associations among northerners to form the NML, the MZL, the UMBC, and others.
A time series plot of MZL, plotted by date of capture, shows an increasing trend reflecting the growth that postsmolts experience during early marine residence (Fig.
The approval is based on results from the multi-center, open-label single arm, Phase 2 PCYC-1121 trial assessing the safety and efficacy of Imbruvica in 63 patients with MZL who received at least one prior therapy, including all 3 subtypes: mucosa-associated lymphoid tissue (MALT; n=32), nodal MZL (NMZL; n=17), and splenic MZL (SMZL; n=14).
Following approval, MZL will be the fifth unique type of blood cancer indication for IMBRUVICA, according to the company.
3) Other studies also reported expression of LMO2 and HGAL in a significant percentage of FLs, including CD10- and/or BCL2--FL or interfollicular/diffuse component of FL, although a few cases of MZL showed weak LMO2 expression.